Investigational New Drugs

, Volume 26, Issue 1, pp 75–79 | Cite as

Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)

  • Joseph G. KattanEmail author
  • Fady S. Farhat
  • Georges Y. Chahine
  • Fady L. Nasr
  • Walid T. Moukadem
  • Fariha C. Younes
  • Nadine J. Yazbeck
  • Marwan G. Ghosn
  • Cancer Research Group


Treatment options for patients with hormone refractory prostate cancer (HRPC) showed unsatisfactory outcomes. Docetaxel-based combinations could offer more promising and tolerated results. A phase II trial was conducted with the combination of zoledronic acid, docetaxel and estramustine. Eligibility consisted of metastatic prostate adenocarcinoma with objective progression or rising prostate specific antigen levels (PSA) despite androgen deprivation therapy. Zoledronic acid was given at a dose of 4 mg on day 1, docetaxel (25 mg/m2) on days 1, 8 and 15, and estramustine orally at 140 mg two times daily on days 1 to 21 of a 28-day cycle. Twenty-seven patients were enrolled between October 2002 and November 2004. Median age was 68 years (53–83 years). A total of 124 cycles were administered with a median of 4.6 cycles per patient (1–8 cycles). The major toxicities were grades 1 to 3 anemia (55%), fatigue (15%), alopecia (11%) and hypocalcemia (11%). Two patients presented with deep venous thrombosis and died from pulmonary embolism. Another third patient died from Stevens–Johnson syndrome and grade 4 hepatic toxicity. Out of the 25 patients assessed for efficacy, 13 (52%) had a biologic response (>50% PSA decline). Three (21%) patients among the 14 with measurable disease had objective response: 1 complete response (CR) and 2 partial responses (PR). Response duration was 2 months for PR and 4 months for CR. A total of 12 patients (48%) experienced clinical benefit with pain reduction. This combination seemed effective; however toxic deaths especially from venous thrombosis counterbalanced the advantage of this regimen.


Prostate cancer Docetaxel Estramustine phosphate Zoledronic acid Weekly chemotherapy 


  1. 1.
    Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520PubMedCrossRefGoogle Scholar
  2. 2.
    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) TAX 327 Investigators: docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512PubMedCrossRefGoogle Scholar
  3. 3.
    Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM (2005) Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone and prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23:3343–3351PubMedCrossRefGoogle Scholar
  4. 4.
    Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer. A Canadian randomized trial with palliative endpoints. J Clin Oncol 14:1756–1764PubMedGoogle Scholar
  5. 5.
    Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ (2001) Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol 19:2509–2516PubMedGoogle Scholar
  6. 6.
    Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V (1999) Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10:33–38PubMedCrossRefGoogle Scholar
  7. 7.
    Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA (2002) Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 94:1457–1465PubMedCrossRefGoogle Scholar
  8. 8.
    Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M (2004) Zoledronic Acid Prostate Cancer Study Group: long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882PubMedCrossRefGoogle Scholar
  9. 9.
    Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL (2003) Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9:295–306PubMedGoogle Scholar
  10. 10.
    Vordos D, Paule B, Vacherot F, Allory Y, Salomon L, Hoznek A, Yiou R, Chopin D, Abbou CC, de la Taille A (2004) Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. BJU Int 94:524–527PubMedCrossRefGoogle Scholar
  11. 11.
    Berry WR, Dakhil S, Gregurich MA, Asmar L (2001) Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28:8–15PubMedCrossRefGoogle Scholar
  12. 12.
    Beer TM, Pierce WC, Lowe BA, Henner WD (2001) Phase II study of docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12:1273–1279PubMedCrossRefGoogle Scholar
  13. 13.
    Melzak R (1975) The McGill pain questionnaire: major properties and scoring methods. Pain 1:277–299CrossRefGoogle Scholar
  14. 14.
    Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W (1989) Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590–597PubMedGoogle Scholar
  15. 15.
    Fleming TR (1982) One-sample multiple testing procedures for phase II clinical trials. Biometrics 38:143–151PubMedCrossRefGoogle Scholar
  16. 16.
    Hainsworth J (2004) Practical aspects of weekly docetaxel administration schedules. Oncologist 9:538–545PubMedCrossRefGoogle Scholar
  17. 17.
    Ferrero JM, Foa C, Thezenas S, Ronchin P, Peyrade F, Valenza B, Lesbats G, Garnier G, Boublil JL, Tchiknavorian X, Chevallier D, Amiel J (2004) A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer. Oncology 66:281–287PubMedCrossRefGoogle Scholar
  18. 18.
    Chittoor S, Berry W, Loesch D (2005) Phase II study of low dose (weekly) docetaxel and estramustine in elderly males (age ≥75 years) with hormone-refractory prostate cancer or patients age 18 to 74 years with an ECOG performance status of 2 or 3 (“abstract”). Proc Am Soc Clin Oncol 23:4145 (Abstract 4646)Google Scholar
  19. 19.
    Bertelli G, Heouaine A, Arena G, Botto A, Garrone O, Colantonio I, Occelli M, Fea E, Giubergia S, Merlano M (2006) Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. Cancer Chemother Pharmacol 57:46–51PubMedCrossRefGoogle Scholar
  20. 20.
    Moisidis C, Moebus V (2005) Erythema multiforme major following docetaxel. Arch Gynecol Obstet 271:267–269PubMedCrossRefGoogle Scholar
  21. 21.
    Boue F, Zaikas G, Lancar R (1998) Activity of taxotere (docetaxel) as therapy for pretreated HIV-associated Kaposi’s sarcoma: an ANRS trial (“abstract”). Proc Am Soc Clin Oncol 17:47a (Abstract 182)Google Scholar
  22. 22.
    Smith M, Nelson J (2005) Future therapies in hormone-refractory prostate cancer. J Urol 65:9–16Google Scholar
  23. 23.
    Sternberg C, Petrylak D, Witjes F (2007) Satraplatin demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial (“abstract”). Proc Am Soc Clin Oncol 25:239s (Abstract 5019)Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Joseph G. Kattan
    • 1
    • 3
    Email author
  • Fady S. Farhat
    • 1
  • Georges Y. Chahine
    • 1
  • Fady L. Nasr
    • 1
  • Walid T. Moukadem
    • 2
  • Fariha C. Younes
    • 1
  • Nadine J. Yazbeck
    • 1
  • Marwan G. Ghosn
    • 1
  • Cancer Research Group
  1. 1.Hôtel-Dieu de France University HospitalBeirutLebanon
  2. 2.Centre Hospitalier du NordZghortaLebanon
  3. 3.Department of Hematology-OncologyHôtel-Dieu de France University HospitalBeirutLebanon

Personalised recommendations